LONDON – A breakthrough technology for generating fully human T-cell receptors (TCR) is set to deliver next-generation T-cell therapies for treating solid tumors, following the €66 million (US$78.3 million) series A funding of T-knife GmbH.
HONG KONG – Venture capital investment into most sectors in China has generally plunged throughout the COVID-19 pandemic but biotechnology has been a noticeable exception.
Matterhorn Bioscience AG has launched to develop T-cell receptor therapies based on the power of MR1T cells that have been found to find and kill a range of tumors in various tissue organs.
Mantra Bio Inc., of San Francisco, plans to take its new $25 million series A financing and advance its pipeline and partnering efforts for engineering targeted exosome vehicles. The company platform integrates computational approaches, wet biology and robotics to leverage exosome diversity and enable rational design of therapeutics for a range of tissue and cellular targets.
RSS
